Vascular Biogenics Ltd.

Vascular Biogenetics Ltd.

Erez Feige

Eyal Breitbart

Andrea Leubitz

Naamit Sher

Itzhak Mendel

Gideon Halperin

Eti Kovalevski-Ishai

Niva Yacov

Richard Penson

Zeev Ziniuk

Livnat Bangio

Yaniv Salem

Yael Cohen

Oshrat Propheta-Meiran

Andrea Rachel Leubitz

The present disclosure relates to antibodies or antigen binding fragments thereof that specifically bind to Motile Sperm Domain Containing Protein 2 (MOSPD2) and methods of using the same.

Motile sperm domain containing protein 2 antibodies and methods of use thereof

The invention provides methods of reducing or decreasing a size of a tumor or eliminating a tumor by inhibiting, decreasing, or reducing neo-vascularization or angiogenesis in a tumor in a patient by administering an adenovirus comprising a nucleic acid construct comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter. Also provided is a homogeneous population of an adenovirus comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter and its uses thereof.

Treatment methods using adenovirus

The invention provides methods of inducing or improving responsiveness to a VEGF antagonist to a subject or a subject population comprising administering an adenovirus comprising a nucleic acid construct comprising a F AS-chimera gene operably linked to an endothelial cell-specific promoter and administering the VEGF antagonist.

Methods of inducing responsiveness to anti-angiogenic agent

The invention provides methods of inducing or improving responsiveness to a VEGF antagonist to a subject or a subject population comprising administering an adenovirus comprising a nucleic acid construct comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter and administering the VEGF antagonist.

Anti-angiogenic adenovirus vectors, and therapeutic use thereof are provided, and more particularly, but not exclusively, clinical protocols for treatment of solid tumors in patients with an Ad5-PPE-1-3X-fas-chimera adenovirus vector.

Methods for use of a specific anti-angiogenic adenoviral agent

Novel oxidized lipids are provided herein, as well as methods for producing same, and uses thereof in treating or preventing an inflammation associated with endogenous oxidized lipids and related conditions.

Oxidized lipid compounds and uses thereof

The invention provides methods of reducing or decreasing a size of a tumor or eliminating a tumor or inhibiting, decreasing, or reducing neo-vascularization or angiogenesis in a tumor in a patient by administering an adenovirus comprising a nucleic acid construct comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter. Also provided is a homogeneous population of an adenovirus comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter and its uses thereof.

FAS-chimera adenovirus vector

Novel oxidized thiophospholipids are provided herein, as well as methods for producing same, and uses thereof in treating or preventing an inflammation associated with endogenous oxidized lipids and related conditions. Exemplary oxidized thiophospholipid according to embodiments described herein have the formula: wherein X, X, A, A, B', B&#x2033;, D&#x2032; and D&#x2033; are as described herein.

Growing community of inventors

Hemed, Israel

Erez Feige